I prækliniske sårhelingsmodeller har EGFR- selektive tyrosinkinasehæmmere imidlertid vist sig at forsinke sårheling.
However, in preclinical wound healing models EGFR selective tyrosine kinase inhibitors were shown to retard wound healing.